Chemours Reports Q2 2025 Results: Net Sales Rise 4% to $1.6B, Net Loss of $381M; Adjusted EPS at $0.58

Reuters
Aug 06
Chemours Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Net Sales Rise 4% to $1.6B, Net Loss of $381M; Adjusted EPS at $0.58

The Chemours Company has released its financial results for the second quarter of 2025, reporting a 4% increase in net sales to $1.615 billion compared to $1.554 billion in the same quarter of the previous year. This growth was mainly driven by a 3% increase in volume and a 1% rise in price, with significant contributions from the Thermal & Specialized Solutions segment, particularly in Opteon™ Refrigerants. The company reported a net loss attributable to Chemours of $381 million for the quarter, compared to a net income of $60 million in the prior-year quarter. This loss was primarily influenced by litigation-related expenses associated with a settlement with the State of New Jersey. Adjusted net income was $87 million, up from $58 million in the same period last year. Adjusted EBITDA showed a significant increase of 22% year-over-year, reaching $253 million compared to $207 million in the previous year's second quarter. Corporate expenses were reduced by $24 million, largely due to lower costs related to internal reviews and material weakness remediation efforts from 2024. In January 2025, Chemours announced a restructuring program under its Advanced Performance Materials segment to exit its SPS Capstone™ business, with final sales expected in the third quarter of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Chemours Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250805063574) on August 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10